en
0.25
0.5
0.75
1.25
1.5
1.75
2
Whole-exome sequencing reveals defective CYP3A4variants predictive for paclitaxel dose-limiting neuropathy
Published on Jul 21, 20141824 Views
Questions\\ Paclitaxel, a widely-used chemotherapeutic drug, can cause severe peripheral neuropathy, causing dose reductions and treatment suspensions and, when long-lasting, a decrease in the qual
Related categories
Chapter list
Whole-exome sequencing reveals defective CYP3A4 variants predictive for paclitaxel dose-limiting neuropathy00:00
Paclitaxel00:09
Genetic markers of paclitaxelneuropathy - 100:58
Genetic markers of paclitaxelneuropathy - 202:20
Genetic markers of paclitaxelneuropathy - 302:24
Extreme phenotype approach coupled with WES - 102:43
Extreme phenotype approach coupled with WES - 203:05
Extreme phenotype approach coupled with WES - 303:21
Extreme phenotype approach coupled with WES - 403:51
Characteristics of the patients with extreme neuropathy - 103:58
Characteristics of the patients with extreme neuropathy - 204:20
Whole exomesequencing (WES) - 104:39
Whole exomesequencing (WES) - 204:52
Coding variants in PD/PK genes - 105:00
Coding variants in PD/PK genes - 205:37
Rare CYP3A4 high-impact variants in extreme neuropathy patients - 105:48
Rare CYP3A4 high-impact variants in extreme neuropathy patients - 205:52
Rare CYP3A4 high-impact variants in extreme neuropathy patients - 305:57
Rare CYP3A4 high-impact variants in extreme neuropathy patients - 406:24
Rare CYP3A4 high-impact variants in extreme neuropathy patients - 506:28
Rare CYP3A4 high-impact variants in extreme neuropathy patients - 606:32
Screening for CYP3A4 codingvariants - 106:40
Screening for CYP3A4 codingvariants - 207:19
Screening for CYP3A4 codingvariants - 307:23
Screening for CYP3A4 codingvariants - 407:45
Screening for CYP3A4 codingvariants - 508:04
Screening for CYP3A4 codingvariants - 608:09
Screening for CYP3A4 codingvariants - 708:14
Are CYP3A4 defective variants clinically relevant? - 108:31
Are CYP3A4 defective variants clinically relevant? - 208:55
Conclusions - 109:38
Conclusions - 209:51
Conclusions - 309:59
Conclusions - 410:05
Conclusions - 510:13
Acknowledgements10:29